Free Research Reports on These Medical Equipment Stocks -- Corindus Vascular Robotics, Myomo, InspireMD, and MiMedx

NEW YORK, Jan. 31, 2018 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on CVRS, MYO, NSPR, and MDXG which can be accessed for free by signing up to www.wallstequities.com/registration. Research coverage has been initiated by WallStEquities.com on Corindus Vascular Robotics Inc. (NYSE AMER: CVRS), Myomo Inc. (NYSE AMER: MYO), InspireMD Inc. (NYSE AMER: NSPR), and MiMedx Group Inc. (NASDAQ: MDXG). Medical Appliances and Equipment companies engage in the manufacture of medical instruments, such as dental and surgical appliances. These companies tend to offer below-average dividend yields when compared to the wider market. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Corindus Vascular Robotics

Waltham, Massachusetts headquartered Corindus Vascular Robotics Inc.'s stock finished Tuesday's session 0.85% lower at $1.16 with a total trading volume of 521,360 shares. Over the last month and the previous three months, the Company's shares have advanced 16.00% and 5.45%, respectively. Additionally, the stock has gained 127.41% over the past year. The Company's shares are trading above their 50-day moving average by 6.02%. Moreover, shares of the Company have a Relative Strength Index (RSI) of 53.01.  

On January 02^nd, 2018, Corindus Vascular Robotics announced that it is working with Mayo Clinic in a preclinical study about use of telestenting. Telestenting, or the remote robotic treatment for percutaneous coronary intervention (PCI), may enable physicians to conduct procedures from virtually any location, opening opportunities for more patients globally to receive the benefits of this lifesaving procedure. Get the full research report on CVRS for free by clicking below at: www.wallstequities.com/registration/?symbol=CVRS

Myomo

Shares in Cambridge, Massachusetts headquartered Myomo Inc. plummeted 7.53%, ending yesterday's session at $4.42. A total volume of 1.32 million shares was traded, which was above their three months average volume of 1.21 million shares. The stock has gained 13.48% in the past month and 43.51% in the previous three months. The Company's shares are trading 20.39% above their 50-day moving average. Moreover, Myomo's stock has an RSI of 57.59. 

On January 24^th, 2018, Myomo and Massachusetts Life Sciences Center (MLSC) celebrated Myomo's repayment of a $750,000 accelerator loan provided by MLSC in 2011. The Company completed repayment of the loan, which totaled $1,350,618 with interest, on December 13^th, 2017. Myomo Chairman and CEO Paul R. Gudonis presented a ceremonial check to Travis McCready, President and CEO of MLSC, during a ceremony at Myomo's headquarters in the Cambridge Innovation Center. Find your free research report MYO at: www.wallstequities.com/registration/?symbol=MYO

InspireMD

On Tuesday, Tel Aviv, Israel headquartered InspireMD Inc.'s stock skyrocketed 35.35%, to close the day at $0.25. A total volume of 52.64 million shares was traded, which was above their three months average volume of 8.53 million shares. The Company's shares have surged 90.16% in the last month. The stock is trading 21.19% above its 50-day moving average. Additionally, shares of InspireMD have an RSI of 64.02. 

On January 19^th, 2018, InspireMD announced the publication of an independent observational study conducted by Tomoyuki Umemoto, MD and colleagues in the December 2017 issue of the journal EuroIntervention demonstrating the advantage of CGuard™ EPS in reducing stent plaque prolapse (vascular tissue or thrombus protruding through the stent and into the carotid artery following stenting that is vulnerable to embolizing into the brain) in carotid artery stenting patients. Sign up today for the free research report on NSPR at: www.wallstequities.com/registration/?symbol=NSPR

MiMedx Group

Shares in Marietta, Georgia headquartered MiMedx Group Inc. ended the day 1.45% lower at $17.70. A total volume of 2.18 million shares was traded, which was above their three months average volume of 1.90 million shares. The stock has surged 39.81% in the last month, 45.68% in the previous three months, and 125.19% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 37.52% and 29.15%, respectively. Furthermore, shares of MiMedx have an RSI of 81.62. 

On January 17^th, 2018, MiMedx announced that the first patients have been randomized and enrolled in the Company's Phase-3 Investigational New Drug clinical trial for its micronized amniotic tissue, AmnioFix® Injectable, in the treatment of Achilles Tendonitis. The design of the Phase-3 Achilles Tendonitis study will include approximately 158 patients. Wall St. Equities' research coverage also includes the downloadable free report on MDXG at: www.wallstequities.com/registration/?symbol=MDXG

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities